Hypothesis

Chronic antigen exposure drives sustained O-GlcNAc transferase (OGT) activity, leading to O-GlcNAcylation of TET2 at specific serine/threonine residues. This post‑translational modification reduces TET2’s catalytic efficiency toward 5mC oxidation, causing locus‑specific loss of 5hmC at exhaustion‑associated promoters (e.g., Pdcd1, Havcr2) while preserving or increasing 5hmC at effector genes. The resulting epigenetic imbalance reinforces a dysfunctional T‑cell state that persists despite checkpoint blockade.

Mechanistic Rationale

1. OGT‑TET2 Crosstalk – OGT can modify TET2 directly, as shown for other dioxygenases where O‑GlcNAcylation alters substrate binding or protein stability {3}. In T cells, OGT is already known to restrain TET activity genome‑wide; we propose that this restraint is not merely inhibitory but stoichiometrically tunes TET2’s demethylation capacity.
2. Metabolic Sensor – The OGT substrate UDP‑GlcNAc reflects flux through the hexosamine biosynthetic pathway (HBP), which rises with elevated glycolysis and glutaminolysis during chronic infection. High UDP‑GlcNAc thus signals a metabolic state that should dampen TET2‑driven demethylation.
3. Epigenetic Consequence – Reduced TET2 activity at exhaustion loci leads to decreased 5hmC, impaired TDG‑mediated base excision repair, and consequently increased 5mC retention. This methylation state recruits methyl‑binding proteins (e.g., MeCP2) that compact chromatin and suppress transcription of inhibitory receptors, paradoxically stabilizing the exhausted phenotype by limiting feedback repression.
4. Lineage Specificity – Because TET2 also supports effector‑gene demethylation via lineage transcription factors (T‑bet, GATA3, RORγt) {2}, OGT‑mediated modulation would simultaneously affect both arms, predicting a shift in the ratio of effector versus exhaustion marks rather than a global loss of 5hmC.

Testable Predictions

• Prediction 1: In CD8+ T cells from mice with chronic LCMV infection, OGT inhibition (using OSMI‑1) or CRISPR‑mediated Ogt knockout will increase 5hmC levels at Pdcd1 and Havcr2 promoters without globally altering 5hmC, accompanied by reduced surface PD‑1/TIM‑3 expression and enhanced viral clearance.
• Prediction 2: Mass spectrometry of immunoprecipitated TET2 from exhausted versus naïve T cells will reveal higher O‑GlcNAc occupancy on TET2 in the exhausted state, correlating with lower 5hmC catalytic activity in vitro.
• Prediction 3: Rescue experiments expressing an O‑GlcNAc‑resistant TET2 mutant (serine/threonine → alanine) in Ogt‑deficient T cells will restore 5hmC at exhaustion loci and reinstate the exhausted phenotype despite low UDP‑GlcNAc.
• Prediction 4: Pharmacological elevation of UDP‑GlcNAc (via glucosamine supplementation) in acute infection models will mimic chronic‑infection epigenetic signatures, accelerating the onset of exhaustion markers.

Experimental Approach

1. Mouse Models – Use Cd8‑Cre‑Ogtfl/fl mice and controls infected with LCMV clone 13. Validate OGT loss in CD8+ T cells by Western blot and immunofluorescence.
2. Epigenetic Profiling – Perform EM‑seq or oxidative bisulfite sequencing on sorted CD44^hiCD8+ T cells to quantify 5hmC at Pdcd1, Havcr2, Ifng, and Gzmb promoters.
3. Functional Assays – Measure cytokine production (IFN‑γ, TNF‑α), cytotoxic granule release, and viral titers. Assess checkpoint blockade efficacy with anti‑PD‑1 treatment.
4. Biochemical Validation – Conduct immunoprecipitation‑mass spectrometry for O‑GlcNAc on TET2, and in vitro demethylation assays using recombinant TET2 ± O‑GlcNAc modification.
5. Metabolic Manipulation – Treat cells with OSMI‑1, glucosamine, or GFAT inhibitors, and monitor UDP‑GlcNAc levels via LC‑MS/MS.

If OGT‑mediated O‑GlcNAcylation of TET2 is a key metabolic‑epigenetic switch in T‑cell exhaustion, disrupting this link should uncouple nutrient signaling from epigenetic drift, offering a novel avenue to enhance immunotherapy durability.